Beacon Therapeutics has raised a $170 million series B, which the U.K.-based gene therapy biotech will use to push its eye disease candidates through clinical trials. European life-sciences-focused growth fund Forbion led the round, while London-based VC firm Syncona and Oxford Science Enterprises both returned. Source: Fierce Biotech 3/7/2024